PRPH
ProPhase Labs Inc (PRPH)
Healthcare • NASDAQ • $0.14+12.50%
- Symbol
- PRPH
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Price
- $0.14
- Daily Change
- +12.50%
- Market Cap
- $568440
- Trailing P/E
- N/A
- Forward P/E
- 0.25
- 52W High
- $6.70
- 52W Low
- $0.07
- Analyst Target
- N/A
- Dividend Yield
- N/A
- Beta
- 0.17
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of dietary supplements under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster. It also develops BE-Smart Esophageal Pre-Cancer diagnostics screening test for early detection of esophageal cancer; genomics testing technologies to analyze entire genomes, including the genes and chromosomes in deoxyribonucleic acid; DNA Expand, a platform that allows consumers to upload their DNA data from previous DNA tests obtained from other service providers; and LB-1 and LB-2 for the treatment of cancer, inflammator…
Company websiteResearch PRPH on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.